We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    "Cystic adenomatoid malformation of lung"

Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM) (CCAM Steroids)

This study has been terminated.
(Recruitment has been poor. Study drug is being offered as part of standard care of women carrying a pregnancy diagnosed with CCAM)
ClinicalTrials.gov Identifier:
First Posted: May 2, 2008
Last Update Posted: March 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Children's Hospital Medical Center, Cincinnati
Children's Hospital of Philadelphia
Information provided by (Responsible Party):
University of California, San Francisco
Congenital cystic adenomatoid malformations (CCAMs) are theorized to be growing immature lung tissue. Administration of maternal steroids in the mid-trimester may stop the growth or decrease the size of the CCAM, thus increasing normal lung tissue and improving survival in fetuses with large CCAMs. This is a prospective, blinded, randomized trial comparing administration of a single course of antenatal steroids (Betamethasone) to control (i.e., placebo). The primary outcome variable will be incidence of hydrops. One month postnatal survival and relative size of the CCAM as determined by CCAM volume:head circumference ratio (CVR) between treatment/no treatment groups will be secondary outcome variables. Change in size of CCAM will be serially followed for both groups with individual growth curves being plotted prenatally and these will be compared with pathology weigh and volume to evaluate treatment effect. Other prenatal data collected will include: incidence of polyhydramnios, incidence of premature rupture of membranes, incidence of material complications. We will also compare mode of delivery, postnatal respiratory compromise, need for resection in the first week of life, and occurrence of complications during newborn administration

Condition Intervention Phase
Congenital Cystic Adenomatoid Malformation Drug: Betamethasone Drug: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Investigation of Prenatal Steroids for Treatment of Prenatally Diagnosed CCAMs

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Incidence of Hydrops Fetalis [ Time Frame: Delivery, up to approximately 20 weeks post-enrollment ]

Secondary Outcome Measures:
  • Comparison of CCAM Size in Mid-trimester Fetuses (Study/Administration vs Control/Placebo) [ Time Frame: Baseline, Delivery (up to approximately 20 weeks post-enrollment) ]
  • Survival at One-month Between Study and Control Groups. [ Time Frame: 30 days after delivery (up to approximately 24 weeks post-enrollment) ]
    Status of neonate survival 30 days after delivery

Enrollment: 1
Study Start Date: April 2008
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Active Study Group
STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
Drug: Betamethasone
12 mg intramuscularly x 2 doses 24 hours apart
Placebo Comparator: Placebo Group
PLACEBO: IM x 2 doses 24 hours apart
Drug: Placebo
PLACEBO: IM x 2 doses 24 hours apart


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • GA < 26 weeks
  • Maternal age > 18 years of age
  • Singleton pregnancy
  • Normal chromosomes
  • CCAM volume to head circumference ratio (CVR) > 1.4
  • No maternal medical/surgical contraindications
  • No evidence of hydrops
  • Not previously randomization

Exclusion Criteria:

  • Maternal diabetes or use of insulin
  • Preterm labor
  • Multiple congenital anomalies with CCAM
  • Chromosomal anomaly with CCAM
  • Multiple gestation pregnancy with CCAM
  • Not willing to be randomized
  • Unable or unwilling to return to UCSF for second dose of drug or placebo
  • CVR < 1.4
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00670956

United States, California
University of California, San Francisco Fetal Treatment Center
San Francisco, California, United States, 94143
United States, Ohio
Cincinnati Children's Hospital
Cincinnati, Ohio, United States, 45229-3039
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of California, San Francisco
Children's Hospital Medical Center, Cincinnati
Children's Hospital of Philadelphia
Principal Investigator: Timothy M Crombleholme, MD Children's Hospital of Cincinnati
Principal Investigator: Douglas Wilson, MD Children's Hospital of Philadelphia
Principal Investigator: Hanmin Lee, MD University of California, San Francisco
  More Information

Additional Information:
Vu L, Tsao K, Lee H, Nobuhara K, Farmer D, Harrison M, Goldstein RB. Characteristics of congenital cystic adenomatoid malformations associated with nonimmune hydrops and outcome. J Pediatr Surg. 2007 Aug;42(8):1351-6.
Schumacher A, Sidor J, Bühling KJ. [Continuous glucose monitoring using the glucose sensor CGMS in metabolically normal pregnant women during betamethasone therapy for fetal respiratory distress syndrome]. Z Geburtshilfe Neonatol. 2006 Oct;210(5):184-90. German.
Peltoniemi OM, Kari MA, Tammela O, Lehtonen L, Marttila R, Halmesmäki E, Jouppila P, Hallman M; Repeat Antenatal Betamethasone Study Group. Randomized trial of a single repeat dose of prenatal betamethasone treatment in imminent preterm birth. Pediatrics. 2007 Feb;119(2):290-8.
Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004454. Review. Update in: Cochrane Database Syst Rev. 2017 Mar 21;3:CD004454.
Neilson JP. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Obstet Gynecol. 2007 Jan;109(1):189-90.
Tsao K, Hawgood S, Vu L, Hirose S, Sydorak R, Albanese CT, Farmer DL, Harrison MR, Lee H. Resolution of hydrops fetalis in congenital cystic adenomatoid malformation after prenatal steroid therapy. J Pediatr Surg. 2003 Mar;38(3):508-10. Review.
Arca MJ, Teich S. Current controversies in perinatal care: fetal versus neonatal surgery. Clin Perinatol. 2004 Sep;31(3):629-48. Review.
Wilson RD, Baxter JK, Johnson MP, King M, Kasperski S, Crombleholme TM, Flake AW, Hedrick HL, Howell LJ, Adzick NS. Thoracoamniotic shunts: fetal treatment of pleural effusions and congenital cystic adenomatoid malformations. Fetal Diagn Ther. 2004 Sep-Oct;19(5):413-20.
Knox EM, Kilby MD, Martin WL, Khan KS. In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesion: a systematic review. Ultrasound Obstet Gynecol. 2006 Oct;28(5):726-34. Review.
Davenport M, Warne SA, Cacciaguerra S, Patel S, Greenough A, Nicolaides K. Current outcome of antenally diagnosed cystic lung disease. J Pediatr Surg. 2004 Apr;39(4):549-56. Review.
Miller JA, Corteville JE, Langer JC. Congenital cystic adenomatoid malformation in the fetus: natural history and predictors of outcome. J Pediatr Surg. 1996 Jun;31(6):805-8.

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00670956     History of Changes
Other Study ID Numbers: 10-03705
First Submitted: April 30, 2008
First Posted: May 2, 2008
Results First Submitted: March 18, 2015
Results First Posted: March 30, 2015
Last Update Posted: March 30, 2015
Last Verified: March 2015

Keywords provided by University of California, San Francisco:
prenatal steroids
congenital cystic adenomatoid malformation of the lung
prenatal intervention
prenatal diagnosis

Additional relevant MeSH terms:
Cystic Adenomatoid Malformation of Lung, Congenital
Congenital Abnormalities
Lung Diseases
Respiratory Tract Diseases
Respiratory System Abnormalities
Betamethasone benzoate
Betamethasone Valerate
Betamethasone sodium phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents

To Top